{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:59:31Z","timestamp":1792004371896,"version":"4.4.0"},"reference-count":23,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>\n            WCK 5222 is a combination of cefepime and the high-affinity PBP2-binding \u03b2-lactam enhancer zidebactam. The cefepime-zidebactam combination is active against multidrug-resistant Gram-negative bacteria, including carbapenemase-expressing\n            <jats:named-content content-type=\"genus-species\">Acinetobacter baumannii<\/jats:named-content>\n            .\n          <\/jats:p>","DOI":"10.1128\/aac.02146-18","type":"journal-article","created":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T15:13:44Z","timestamp":1548256424000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":48,"title":["The Novel \u03b2-Lactam Enhancer Zidebactam Augments the\n            <i>In Vivo<\/i>\n            Pharmacodynamic Activity of Cefepime in a Neutropenic Mouse Lung\n            <i>Acinetobacter baumannii<\/i>\n            Infection Model"],"prefix":"10.1128","volume":"63","author":[{"given":"S. S.","family":"Bhagwat","sequence":"first","affiliation":[{"name":"Wockhardt Research Centre, Aurangabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Periasamy","sequence":"additional","affiliation":[{"name":"Wockhardt Research Centre, Aurangabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. S.","family":"Takalkar","sequence":"additional","affiliation":[{"name":"Wockhardt Research Centre, Aurangabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. R.","family":"Palwe","sequence":"additional","affiliation":[{"name":"Wockhardt Research Centre, Aurangabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. N.","family":"Khande","sequence":"additional","affiliation":[{"name":"Wockhardt Research Centre, Aurangabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. V.","family":"Patel","sequence":"additional","affiliation":[{"name":"Wockhardt Research Centre, Aurangabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/2049936115621709"},{"key":"e_1_3_3_3_2","volume-title":"Antibiotic resistance (AR) data","author":"Centers for Disease Control and Prevention","year":"2011","unstructured":"Centers for Disease Control and Prevention. 2011. Antibiotic resistance patient safety atlas. Antibiotic resistance (AR) data. Centers for Disease Control and Prevention, Atlanta, GA. https:\/\/gis.cdc.gov\/grasp\/PSA\/MapView.html."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02123-13"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.02.021"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01238-17"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02529-16"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00091"},{"key":"e_1_3_3_9_2","volume-title":"ASM Microbe, Boston, MA","author":"Palwe SR","year":"2016","unstructured":"Palwe SR, Biniwale SS, Khande HN, Joshi PR, Bhagwat SS, Patel MV. 2016. Cefepime (FEP) and WCK 5107 (zidebactam, ZID) mediated dual PBP engagement at sub-MIC concentrations drive cidality against diverse \u03b2-lactamases expressing Gram-negatives, poster no. Sunday 448. ASM Microbe, Boston, MA. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_3_10_2","volume-title":"ASM Microbe, Boston, MA","author":"Palwe SR","year":"2016","unstructured":"Palwe SR, Joshi PR, Khande HN, Biniwale SS, Bhagwat SS, Patel MV. 2016. WCK 5107 (zidebactam, ZID): a pan Gram-negative \u03b2-lactam enhancer augmenting \u03b2-lactam pharmacodynamics in wild type and carbapenemase producers (CP), poster no. Sunday 438. ASM Microbe, Boston, MA. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.4.812"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00072-17"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx050"},{"key":"e_1_3_3_14_2","volume-title":"ASM Microbe, Boston, MA","author":"Takalkar SS","year":"2016","unstructured":"Takalkar SS, Kulkarni AM, Chavan RP, Zope VS, Joshi PR, Khande HS, Satav JS, Bhagwat SS, Patel MV. 2016. WCK 5222 [cefepime (FEP)-WCK 5107 (zidebactam, ZID)]: thigh and lung PK\/PD studies against higher MIC OXA carbapenemase-expressing A. baumannii (AB), poster no. Sunday 441. ASM Microbe, Boston, MA. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00948-18"},{"key":"e_1_3_3_16_2","volume-title":"ID Week","author":"Abuhussain SA","year":"2018","unstructured":"Abuhussain SA, Avery LM, Abdelraouf K, Nicolau P. 2018. Assessment of the in vivo efficacy of WCK 5222 (cefepime-zidebactam) against carbapenem-resistant Acinetobacter baumannii in the neutropenic murine thigh infection model, poster no. 1336. ID Week, San Francisco, CA."},{"key":"e_1_3_3_17_2","volume-title":"ASM Microbe, New Orleans, LA","author":"Bhagwat SS","year":"2017","unstructured":"Bhagwat SS, Takalkar SS, Chavan RP, Friedland HD, Patel MV. 2017. WCK 5222 [cefepime (FEP) + WCK 5107 (zidebactam, ZID)]: in vivo demonstration of ZID-mediated \u03b2-lactam enhancer effect leading to lowering of FEP %fT>MIC against P. aeruginosa (PA) and A. baumannii (AB), poster no. Saturday 284. ASM Microbe, New Orleans, LA. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_3_18_2","volume-title":"ECCMID","author":"Chugh R","year":"2017","unstructured":"Chugh R, Lakdavala F, Friedland HD, Bhatia A. 2017. Safety and pharmacokinetics of multiple ascending doses of WCK 5107 (zidebactam) and WCK 5222 (cefepime and zidebactam), poster no. P1301. ECCMID, Vienna, Austria."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.18.6.906"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02029-13"},{"key":"e_1_3_3_21_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. CLSI document M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"10"},{"key":"e_1_3_3_22_2","volume-title":"ASM Microbe, New Orleans, LA","author":"Traczewski MM","year":"2017","unstructured":"Traczewski MM, Bhagwat SS. 2017. Cefepime-zidebactam (FEP-ZID) or WCK 5222 tier 2 broth microdilution MIC quality control versus E. coli ATCC 25922, K. pneumoniae ATCC 700603, P. aeruginosa ATCC 27853, A. baumannii NCTC 13304 and E. coli NCTC 13353, poster no. Saturday 284. ASM Microbe, New Orleans, LA. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_3_23_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 28th ed. CLSI document M100. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"28"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00682-18"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02146-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02146-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:41:01Z","timestamp":1645479661000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02146-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1128\/AAC.02146-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.02146-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"2018-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02146-18"}}